UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,078 shares of the biotechnology company’s stock after selling 4,880 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in REGENXBIO were worth $693,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in RGNX. Integral Health Asset Management LLC boosted its stake in shares of REGENXBIO by 25.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after buying an additional 37,055 shares during the period. Bank of New York Mellon Corp boosted its position in REGENXBIO by 9.3% during the second quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company’s stock valued at $3,972,000 after buying an additional 28,846 shares during the period. Millennium Management LLC grew its stake in shares of REGENXBIO by 84.8% during the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock valued at $3,586,000 after buying an additional 140,666 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of REGENXBIO by 4.3% in the second quarter. Principal Financial Group Inc. now owns 225,417 shares of the biotechnology company’s stock worth $2,637,000 after buying an additional 9,206 shares during the period. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Trading Down 4.6 %

Shares of NASDAQ RGNX opened at $7.41 on Friday. The firm has a fifty day simple moving average of $9.67 and a two-hundred day simple moving average of $11.27. REGENXBIO Inc. has a 12 month low of $7.38 and a 12 month high of $28.80. The firm has a market capitalization of $367.13 million, a PE ratio of -1.47 and a beta of 1.24.

Analyst Upgrades and Downgrades

RGNX has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Morgan Stanley restated an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Raymond James reiterated an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Finally, HC Wainwright cut their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.27.

Insider Activity at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 46.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.13% of the stock is owned by corporate insiders.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.